Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clarithromycin-Resistant H pylori Faces New Foe

Clarithromycin-Resistant H pylori Faces New Foe News & Analysis News From the Food and Drug Administration Clarithromycin-Resistant H pylori sis, the first triple-combination therapy that tion, sweat chloride concentration, and re- Faces New Foe treats the underlying cause of most pa- spiratory quality of life compared with the The FDA has approved a combination drug tients’ disease has received FDA approval. tezacaftor-ivacaftor group. for Helicobacter pylori infection that’s Marketed as Trikafta, the drug com- Serious adverse events associated with designed to address high rates of resistance bines elexacaftor, tezacaftor, and ivacaftor. Trikafta in both trials were rash and influ- to standard clarithromycin-based treat- The trio improves the function of the abnor- enza. Common adverse events included ment, according to manufacturer RedHill mal cystic fibrosis transmembrane conduc- headache, upper respiratory tract infec- Biopharma Ltd of Tel Aviv, Israel. In 2017, tance regulator (CFTR) protein resulting tion, abdominal pain, diarrhea, and in- the World Health Organization designated from a genetic mutation that’s responsible creased liver enzymes. the need for new antibiotics against H pylori for about 90% of cystic fibrosis cases. The as a high priority. drug is indicated for patients aged 12 years New Report Examines Drug Shortages A combination of the antibiotics rifabu- or older http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Clarithromycin-Resistant H pylori Faces New Foe

JAMA , Volume 322 (21) – Dec 3, 2019

Clarithromycin-Resistant H pylori Faces New Foe

Abstract

News & Analysis News From the Food and Drug Administration Clarithromycin-Resistant H pylori sis, the first triple-combination therapy that tion, sweat chloride concentration, and re- Faces New Foe treats the underlying cause of most pa- spiratory quality of life compared with the The FDA has approved a combination drug tients’ disease has received FDA approval. tezacaftor-ivacaftor group. for Helicobacter pylori infection that’s Marketed as Trikafta, the drug com- Serious...
Loading next page...
 
/lp/american-medical-association/clarithromycin-resistant-h-pylori-faces-new-foe-DMcUQ2zTen

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2019.19479
Publisher site
See Article on Publisher Site

Abstract

News & Analysis News From the Food and Drug Administration Clarithromycin-Resistant H pylori sis, the first triple-combination therapy that tion, sweat chloride concentration, and re- Faces New Foe treats the underlying cause of most pa- spiratory quality of life compared with the The FDA has approved a combination drug tients’ disease has received FDA approval. tezacaftor-ivacaftor group. for Helicobacter pylori infection that’s Marketed as Trikafta, the drug com- Serious adverse events associated with designed to address high rates of resistance bines elexacaftor, tezacaftor, and ivacaftor. Trikafta in both trials were rash and influ- to standard clarithromycin-based treat- The trio improves the function of the abnor- enza. Common adverse events included ment, according to manufacturer RedHill mal cystic fibrosis transmembrane conduc- headache, upper respiratory tract infec- Biopharma Ltd of Tel Aviv, Israel. In 2017, tance regulator (CFTR) protein resulting tion, abdominal pain, diarrhea, and in- the World Health Organization designated from a genetic mutation that’s responsible creased liver enzymes. the need for new antibiotics against H pylori for about 90% of cystic fibrosis cases. The as a high priority. drug is indicated for patients aged 12 years New Report Examines Drug Shortages A combination of the antibiotics rifabu- or older

Journal

JAMAAmerican Medical Association

Published: Dec 3, 2019

There are no references for this article.